Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dipyridamol kinetics

C Mahony, K M Wolfram, D M Cocchetto

    Clinical Pharmacology and Therapeutics
    |March 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    This study on dipyridamole kinetics found significant variability in drug concentrations, particularly between sexes. These findings question current empirical dosing practices for this antiplatelet medication.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Paving the way for application of next generation risk assessment to safety decision-making for cosmetic ingredients.

    Regulatory toxicology and pharmacology : RTP·2021
    Same author

    Highlight report: 'Big data in the 3R's: outlook and recommendations', a roundtable summary.

    Archives of toxicology·2018
    Same author

    A strategy for structuring and reporting a read-across prediction of toxicity.

    Regulatory toxicology and pharmacology : RTP·2015
    Same author

    Pharmacometrics and the transition to model-based development.

    Clinical pharmacology and therapeutics·2007
    Same author

    Recovery of peroxides in saliva during home bleaching--influence of smoking.

    Journal of oral rehabilitation·2006
    Same author

    An exposure-based risk assessment approach to confirm the safety of hydrogen peroxide for use in home tooth bleaching.

    Regulatory toxicology and pharmacology : RTP·2005
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Area of Science:

    • Pharmacokinetics
    • Clinical Pharmacology

    Background:

    • Dipyridamole is an antiplatelet agent used clinically.
    • Understanding its pharmacokinetic profile is crucial for effective therapeutic use.

    Purpose of the Study:

    • To investigate the pharmacokinetic properties of dipyridamole after intravenous and oral administration.
    • To assess factors influencing dipyridamole concentration variability.

    Main Methods:

    • Six healthy subjects received intravenous and oral dipyridamole doses.
    • Blood samples were collected over 3 days and analyzed using high-performance liquid chromatography.
    • Pharmacokinetic parameters including half-life, clearance, and volume of distribution were calculated.

    Main Results:

    Related Experiment Videos

  • Intravenous dipyridamole exhibited a terminal half-life of 11.6 hours, with a plasma clearance of 8.27 L/hr.
  • Oral administration showed an absorption lag time of 34-75 minutes and a systemic availability of 43%.
  • A notable difference was observed, with female subjects showing concentration increases 6-10 hours post-IV dose, unlike males.

    • Conclusions:

    • Dipyridamole exhibits significant pharmacokinetic variability, influenced by administration route and potentially sex.
    • The observed variability raises concerns regarding the efficacy and safety of current empirical dosing regimens.
    • Further research is warranted to optimize dipyridamole dosage strategies.